Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad
Published in
Expert Opinion on Investigational Drugs
Introduction Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activi...
Miguez-Rey, Enrique Choi, Dasom Kim, Seungmin Yoon, Sangwook Săndulescu, Oana
Published in
Expert Opinion on Investigational Drugs
Introduction Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to preven...
Ngo, Binh T Marik, Paul Kory, Pierre Shapiro, Leland Thomadsen, Raphael Iglesias, Jose Ditmore, Stephen Rendell, Marc Varon, Joseph Dubé, Michael
...
Published in
Expert opinion on investigational drugs
Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.Methods: We searched the major national registries, pubmed.org, and the ...
Doggrell, Sheila A
Published in
Expert opinion on investigational drugs
In clinical trial for the Ebola virus, the broad-spectrum anti-viral agent remdesivir was shown to have a good safety profile. Remdesivir is now being tested in severe COVID-19. The Gilead Sciences SIMPLE trial suggests that the short-term use of remdesivir probably does not increase mortality dramatically or have serious short-term toxicity when u...
Doggrell, Sheila A
Published in
Expert opinion on investigational drugs
Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19. This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomized trial in hospitalized subjects with COVID-9 in a respiratory sample and pneumonia. A...
Battaglini, Denise Robba, Chiara Ball, Lorenzo Cruz, Fernanda Ferreira Silva, Pedro Leme Pelosi, Paolo Rocco, Patricia Rieken Macedo
Published in
Expert opinion on investigational drugs
Kuhne, Sebastiaan Wijtmans, Maikel Lim, Herman D Leurs, Rob de Esch, Iwan J P
Published in
Expert Opinion on Investigational Drugs
A challenging feature in H(3)R research is the multifaceted role of the receptor at a molecular/biochemical level, which can complicate targeting by small molecules at several (pre)clinical levels. Accordingly, H(3)R antagonists/inverse agonists require further testing to pinpoint the determinants for clinical efficacy and to aid in the final push ...
Narayanan, Aarthi Bailey, Charles Kashanchi, Fatah Kehn-Hall, Kylene
Published in
Expert opinion on investigational drugs
the search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and economic challenges to the human population. Many of these infectious agents are not only endemic threats in different parts of the globe, but ar...
Greenberg, Richard N Kennedy, Jeffrey S
Published in
Expert opinion on investigational drugs
Due to concern over i) expiration of currently available calf-lymph vaccine (Dryvax); ii) calf lymph as a vaccine (bovine spongiform encephalopathy [BSE], other possible contaminations and animal welfare); and iii) use of variola as a weapon for bioterrorism, a new and safer vaccinia-based smallpox vaccine derived from new cell culture-based techno...
Wu, Chang-Jer Chan, Yi-Lin
Published in
Expert opinion on investigational drugs
Until the appearance of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV) in early 2003, coronavirus infection was not considered to be serious enough to be controlled by either vaccination or specific antiviral therapy. It is now believed that the availability of antiviral drugs effective against SARS-CoV will be ...
